It’s a game changer in the fight against cancer – but what is proton beam therapy and how does it work? .Watch this to learn more about this highly precise treatment option for kids and adults with complex diagnoses.

We’re proud of you @RandyMoss and honored to be part of your journey.

RT @LCI_YWBP: Survivorship begins at #cancer diagnosis! Required registration by Aug 28 to save your seat for this community lunch event ho….

RT @LCI_YWBP: Survivorship begins at #cancer diagnosis. Join @LevineCancer Sat, Sept 6 for a day of Empowerment & Wellness for Survivors, T….

RT @WakeForestIM: Top Papers (7/10): Dr. Nilanjan Ghosh, MD, PhD of @LevineCancer made the list of top papers of 2024 in the Department of….

Congrats to our cancer program leader Dr. Ruben Mesa (@mpdrc) on earning the prestigious Ernest Beutler Lecture and Prize! Dr. Mesa has been a pioneer in the groundbreaking research & development of new therapies for myeloproliferative neoplasms (MPNs). @AtriumHealthWFB.

Potentially game-changing work underway for multiple myeloma, led by @PlasmaCellPete and presented at #ASCO25 👏👇.

That's a wrap for #ASCO25! We came, we collaborated, we worked to conquer cancer.

A possible game-changer for those battling relapsed/refractory multiple myeloma (RRMM). 🩸Our study shows that 33% of patients treated with cilta-cel have remained progression-free for ≥5 years. #ASCO25 Link:

Exciting news for childhood cancer survivors! A new AI model using simple 10-second ECGs can predict the risk of developing cardiomyopathy within 5 years. This can help identify those needing early heart screenings. 💖 #ASCO25 @AtriumHealthWFB Link:

RT @mpdrc: Ropeginterferon Alfa-2b Demonstrates Superior Efficacy & Safety to Anagrelide as 2L for ET - honored to have shared this yesterd….

Small steps, big impacts for cancer survivors! Our study shows the AH-HA tool significantly boosts CV health discussions and even helps with weight loss. Survivors using AH-HA saw more weight reduction compared to usual care. @AtriumHealthWFB #ASCO25 Link:

Promising results for patients with essential thrombocythemia (ET) 🩸Dr. Ruben Mesa (@mpdrc) highlights Phase 3 SURPASS-ET trial of ropeginterferon at #ASCO25, offering new hope for ET patients with better blood count control & reduced JAK2 mutation. Link:

RT @AshleySumrallMD: Our @LevineCancer @AtriumHealthWFB crew with the always-inspiring @ASCO CEO @CliffordHudis & our incredible leader @AS….

Pre-treatment DPYD genotyping can save 💵 & reduce severe side effects from fluoropyrimidine therapy. By identifying genetic variants beforehand, hospitals can cut costs & improve patient outcomes. 🏥💊 #ASCO25 Link:

Our largest study yet on #DPYD genotype-guided chemotherapy shows that personalized dosing can help reduce severe side effects and hospitalizations. This means safer, more effective treatment options for patients with DPYD variants. 💊🧬 #ASCO25 Link:

Older cancer survivors tried muscadine grape extract for 12 weeks. While it didn't beat fatigue or boost quality of life, it did improve physical function & gait speed. Next steps, find out how it affects oxidative stress & inflammation. 🍇 #ASCO25 Link:

Neuro-onc study alert 🧠.@AshleySumrallMD presents research that shows dordaviprone (ONC201) is effective and safe for treating recurrent H3 K27M-mutant diffuse midline glioma. With positive responses in both adults and kids, it offers hope. #ASCO25 Link:

Progress in the fight against advanced head and neck cancer! 🧬 Our latest study shows Tumor Mutation Burden (TMB) and specific gene mutations associated with patient response to PD-1 inhibitors, potentially guiding personalized treatments. #ASCO25 Link:

Battling financial toxicity through screening 💵.Dr. Greg Knight presents his latest research at #ASCO25 that shows asking our patients regularly about the help they need can lead to finding more solutions for them. Read more:

Education session 📘 🩺.Dr. Erin Crane discusses treatment options for rare uterine cancers: surgery and chemo for early-stage serous carcinomas, targeted therapy for advanced, & surgery, chemo, and radiation for mesonephric-like endometrial. #ASCO2025